Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Stroke
Lancet 389:641-654, Hankey, G.J., 2017
Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome
Ann Neurol 79:560-568, Park, J.M.,et al, 2016
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
NEJM 367:817-825, The SPS3 Investigators, 2012
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Effect of Home Testing of International Normalized Ratio on Clinical Events
NEJM 363:1608-1620, Matchar,D.B.,et al, 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Aspriin and Clopidogrel Compared with Colpidogrel Alone After Recent Ischaemic Stroke or Transient Ischaemic Attack in High-Risk Patients (MATCH): Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:331-337, Diener,H.-C.,et al, 2004
A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke
NEJM 345:1444-1451,1493, Mohr,J.P.,et al, 2001
The North American Symptomatic Carotid Endarterectomy Trial, Surgical Results in 1415 Patients
Stroke 30:1751-1758,1745, Ferguson,G.G.,et al, 1999
Prevent of a 1st Stroke by Transfusions in Children/Sickle Cell Anemia & Abnorm Results on Transcr Doppler Ultrasonog
NEJM 339:5-11, Adams,R.J.,et al, 1998
Influence of Cholesterol on Survival After Stroke:Retrospective Study
BMJ 314:1584-1588, Dyker,A.G.,et al, 1997
Discontinuation of Long-Term Transfusion Therapy in Patients with Sickle Cell Disease & Stroke
J Pediatr 131:757-760, Rana,S.,et al, 1997
Bleeding During Antithrombotic Therapy in Patients with Atrial Fibrillation
Stroke Prevention in Atrial Fib Invest, Arch Int Med 156:409-4161996., , 1996
Ticlopidine for Prevention of Stroke
The Medical Letter, 34:65-661992., , 1992
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg Aspirin as Secondary Prophylaxis After Cerebrovascular Ischaemic Events
The SALT Coll Group, Lancet 338:1345-13491991., , 1991
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation
NEJM 392:2403-2412, 2473, Kharbanda,R.K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
The Role of GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists in Primary Stroke Prevention
Stroke 56:e307-e309, Inikori,E.,et al, 2025
The Multifactorial Nature of Ischemic Stroke in Malignancy
Stroke 56:e303-e306, Doyle,C.L.,et al, 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Recurrent Ischemic Stroke in Patients with Atrial Fibrillation Whle Receiving Oral Anticoagulants
JAMA Neurol 81:805-813, Hindsholm,M.F.,et al, 2024
A 25-Year-Old Woman With Eye Swelling and HEadache
Neurol 100:879-883, Hehir,A.,et al, 2023
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Recommendations for the Establishment of Stroke Systems of Care
Stroke 50:e1-e24, Adeoye, O.,et al, 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
NEJM 379:215-225, 291, Johnston, S.C.,et al, 2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
NEJM 378:2191-2201, Hart, R.G.,et al, 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Long-Term Results of Stenting Versus Endarterectomy for Carotid-Artery Stenosis
NEJM 374:DOI: 10.1056/NEJMoa1505215,, Brott, T.G.,et al, 2016
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
NEJM 374: DOI:10.1056/NEJMoa1506930, Kernan, W.N.,et al, 2016